Compare Carvana Co (CVNA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs TG Therapeutics Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Carvana Co is far larger — about 8.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and TG Therapeutics Inc for 16 Days on average.
| CVNA | TGTX | |
|---|---|---|
Market Cap | $69.55B | $8.16B |
Volume | 7,671,750 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $59.06 |
52-Week Low | $56.27 | $26.94 |
Typical Hold Time | 28 Days | 16 Days |
Enterprise Value | $72.04B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% with strong fundamental momentum including 10 consecutive quarters of record profitability. Revenue surged 52% in Q2 FY26 to $20.32B annually, while net income reached $1.41B with a 6.26% margin. Technical indicators show bearish momentum with key support at $61-62, though RSI levels remain neutral. The company continues expanding capacity to meet robust demand, with same-day delivery recently launched in Minneapolis.
CVNA presents growth potential with analyst consensus target of $84.07 (33% upside), but faces risks from high debt levels ($5.26B long-term) and volatile cash flow patterns. The stock's elevated P/E of 33.44 and EV/EBITDA of 507.31 suggest premium valuation, requiring sustained execution to justify. Competitive pressures in online auto retail and interest rate sensitivity remain key watchpoints for investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
